A Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety and Tolerability of Progressive Dose-Escalation of Pramlintide in Obese Subjects with Non-Insulin Treated Type 2 Diabetes and Obese Non-Diabetic Subjects